Completed Clinical Trials

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

By April 24, 2017 No Comments


Malignant Mesothelioma

Estimated Enrollment: 46

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: CALGB-30601|U10CA031946|CDR0000558362

Study First Received: July 30, 2007

Last Updated: July 11, 2016

Estimated Primary Completion Date: February 2010


Primary Outcome Measures:

24 Week Progression Free Survival|Number of Participants With Overall Tumor Response|Overall Survival|Progression Free Survival

Sponsors and Collaborators:

Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)

Website Link:

Leave a Reply

Call Now